Ritholtz's Reads: Drug Prices, Benchmarking and Trump

Barry Ritholtz is a Bloomberg View columnist. He founded Ritholtz Wealth Management and was chief executive and director of equity research at FusionIQ, a quantitative research firm. He blogs at the Big Picture and is the author of “Bailout Nation: How Greed and Easy Money Corrupted Wall Street and Shook the World Economy.”
Read More.
a | A

My when is it going to stop raining in Portland? Turkish coffee reads:

  • Fund managers lose out from benchmarking (FT), see also The Pitfalls of Benchmarking (A Wealth of Common Sense)
  • A Cheaper Way to Battle Recession (Bloomberg View)
  • The Amazon Tax (Stratechery)
  • Why Don’t Investors Stay True to Their Principles? Think Self-Deception (ThinkAdvisor), see also Buy & Hold Can Be Risky, Too (Capital Spectator)
  • How Americans’ Perceptions of the Economy Have Changed in Just Three Months (Real Time Economics)
  • The Koch Brothers Have Started a New Family Office to Quietly Invest Their Fortune (Bloomberg)
  • Ouch! Name-brand prescription drug prices in the US have doubled in the last five years (Quartz)
  • DOJ’s Clear Threat to Go After Apple’s Source Code (emptywheel)
  • The macabre truth of gun control in the US is that toddlers kill more people than terrorists do (Guardian)
  • How to Steal a Nomination From Donald Trump (Bloomberg)

Feel the Burn

This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.

To contact the author of this story:
Barry Ritholtz at britholtz3@bloomberg.net

To contact the editor responsible for this story:
Zara Kessler at zkessler@bloomberg.net